Heyingwuzi formulation alleviates diabetic retinopathy by promoting mitophagy via the HIF-1α/BNIP3/NIX axis

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

158

Figures (1-9)

Tables (1-2)

Sum=245

Publishing Process of This Article

Item

Count

Browse

Download

Sum=23

Jun 15, 2024 (publication date) through Jun 30, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Diabetes. Jun 15, 2024; 15(6): 1317-1339
Published online Jun 15, 2024. doi: 10.4239/wjd.v15.i6.1317

Table 1 Primer sequences used for quantitative reverse transcription-polymerase chain reaction

Citation: Wu JJ, Zhang SY, Mu L, Dong ZG, Zhang YJ. Heyingwuzi formulation alleviates diabetic retinopathy by promoting mitophagy via the HIF-1α/BNIP3/NIX axis. World J Diabetes 2024; 15(6): 1317-1339
URL: https://www.wjgnet.com/1948-9358/full/v15/i6/1317.htm
DOI: https://dx.doi.org/10.4239/wjd.v15.i6.1317